vimarsana.com

ரட்ஜர்ஸ் பள்ளி ஆஃப் டெஂடல் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Peter Rinaldi, DMD, AAACD, is being recognized by Continental Who s Who

Dental School Researcher Gets Approval to Begin Clinical Trials for Cancer Therapy

Rutgers University Treatment Uses Protein found in Oral Bacterium A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration (FDA) approval to begin a phase I clinical trial to treat cancer patients with a therapy based on Kachlany’s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. The approval clears the way for Kachlany’s company, Actinobac Biomed, to begin the trial in patients who have relapsed or refractory leukemia or lymphoma. Their experimental drug, Leukothera, has additionally proven effective in treating autoimmune diseases in animals, and Actinobac is also developing its use for that purpose.

Trial to test oral bacteria protein against cancer

Certain mouthwashes might stop COVID-19 virus transmission

 E-Mail Researchers at Rutgers School of Dental Medicine have found evidence that two types of mouthwash disrupt the COVID-19 virus under laboratory conditions, preventing it from replicating in a human cell. The study, published in the journal Pathogens, found that Listerine and the prescription mouthwash Chlorhexidine disrupted the virus within seconds after being diluted to concentrations that would mimic actual use. Further studies are needed to test real-life efficacy in humans. The study was conducted in a lab using concentrations of the mouthwash and the time it would take to contact tissues to replicate conditions found in the mouth, said Daniel H. Fine, the paper s senior author and chair of the school s Department of Oral Biology.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.